#3048
Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction:
Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Schinzari G,
Maiorano B,
Rossi E,
Bianchi A,
Chiloiro S,
Keywords:
pNET,
non-functioning,
sporadic,
somatostatin analogs,
surveillance,
#3021
Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction:
In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Gertner J
Authors:
Gertner J,
McSweeney A,
Furtado O'Mahony L,
Quaglia E,
John A,
Keywords:
homecare,
#3009
OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics
Introduction:
Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Hautefeuille V
Authors:
Hautefeuille V,
Do Cao C,
Coriat R,
Dominguez S,
Mineur L,
Keywords:
Patients’ perception of information,
Quality of Life,
Lanreotide,